Market Cap: $3.08B
VI
Viking Therapeutics, Inc.
VKTX
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $3.08B
Viking Therapeutics, Inc. (https://cashumarkets.com/stock/vktx) is making significant inroads into the competitive landscape of obesity treatment with its innovative drug candidates VK2735 and VK3019.…
Viking Therapeutics, Inc. (https://cashumarkets.com/stock/vktx) is making significant strides in the biopharmaceutical landscape, particularly in addressing obesity—a growing public health crisis. As…
Viking Therapeutics, Inc. (https://cashumarkets.com/stock/vktx), a biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders, is currently spotlighted…
Viking Therapeutics (Ticker: VKTX) initiates an important Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor agonist targeting obesity. This trial represents a significant develo…
Viking Therapeutics (Ticker: VKTX) makes a notable stride in its commitment to combat obesity and related metabolic disorders with the initiation of a Phase 1 clinical trial for VK3019. This novel dua…
Viking Therapeutics (Ticker: VKTX) announces a strategic leadership change that signals a renewed commitment to addressing the pressing issue of obesity treatment in the pharmaceutical sector. With th…
Viking Therapeutics (Ticker: VKTX) appoints Dr. Hubert C. Chen as chief medical officer, a strategic decision aimed at strengthening its leadership in the metabolic and endocrine disorder sectors. Dr.…
Viking Therapeutics appoints a new Chief Medical Officer, enhancing its commitment to innovative therapies for metabolic conditions that impact millions. Dr. Hubert C. Chen, a veteran with over two de…
Viking Therapeutics (Ticker: VKTX) is making strides in the field of obesity therapeutics, with pivotal developments surrounding its investigational drug, VK2735. The company is set to report importan…
Viking Therapeutics (Ticker: VKTX) faces a pivotal moment as it advances its promising obesity drug candidate, VK2735, which could significantly reshape the company's long-term prospects in the biopha…
Viking Therapeutics Advances VK2735 Program to Combat Obesity Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, is actively advancing its VK2735 program, a novel du…
Viking Therapeutics, a biopharmaceutical company dedicated to developing therapies for metabolic disorders, recently makes significant strides in its clinical programs. The company's focus is on VK273…
Novo Nordisk's Strategic Move with Higher-Dose Wegovy Enhances Competitive Landscape in Weight Loss Treatments Novo Nordisk effectively pivots to regain market presence in the competitive weight loss…
Novo Nordisk's New Dose of Wegovy: A Strategic Move in the Obesity Treatment Market Novo Nordisk positions itself to bolster its competitive stance in the obesity treatment market with the FDA's recen…
Viking Therapeutics Enhances Strategic Presence at Upcoming Healthcare Conferences Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorde…
Viking Therapeutics Advances Metabolic Therapies Amid Upcoming Conferences Viking Therapeutics, Inc., a clinical-stage biopharmaceutical firm focused on innovative treatments for metabolic and endocri…
Viking Therapeutics Pursues Innovative Solutions for Metabolic Disorders Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is actively advancing its portfolio of therapies aimed a…
Novo Nordisk Faces Strategic Challenges Following REDEFINE 4 Trial Results Novo Nordisk's recent disclosure of disappointing results from its REDEFINE 4 clinical trial raises significant concerns rega…
Market Shake-Up Following Novo Nordisk's Clinical Trial Results Novo Nordisk's recent announcement regarding the failure of its REDEFINE 4 clinical trial has sent shockwaves through the obesity and di…
Viking Therapeutics Observes Shifts in Obesity Therapeutics Landscape Amidst the continued development of obesity therapeutics, Viking Therapeutics plays a pivotal role in the ongoing dialogue surroun…
Viking Therapeutics Faces Increased Skepticism Amidst Elevated Short Interest In recent days, Viking Therapeutics Inc. experiences a notable surge in short interest, which raises concerns regarding th…
Viking faces heightened scrutiny ahead of clinical catalysts Clinical-milestone uncertainty fuels market skepticism around Viking Therapeutics Viking Therapeutics is experiencing elevated market scrut…
Market attention sharpens as short interest rises for Viking Therapeutics Viking Therapeutics is seeing heightened scrutiny from market participants as exchange-reported short interest grows. The incr…
Viking Therapeutics and the rise of clinically credible, portable dosing in wellness Viking Therapeutics, a developer of metabolic and endocrine therapies, is positioned within a broad industry shift…
Viking targets pivotal Phase 3 for oral obesity therapy Viking Therapeutics is advancing an oral obesity drug into Phase 3 development, marking a major step for the San Diego biotech’s metabolic disea…